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The incidence of invasive fungal infections, par-
ticularly those caused by Candida species, has in-
creased worldwide over the last 20 years.1–3 It is
clear that Candida has emerged as one of the most
important pathogens that causes bloodstream
infection.4–6 An understanding of the recent epi-
demiology of disease burden, impact on mortality,
species distribution and antifungal susceptibility
is important to the clinician’s ability to manage
adequately patients with invasive candidiasis.
The aim of this review is to summarize the cur-
rently available data on the epidemiology of 
invasive candidiasis worldwide, particularly those
from Taiwan.
As a result of the wide disease spectrum 
related to Candida infection in humans, invasive
candidiasis described in this article includes can-
didemia, deep tissue infection and disseminated
candidiasis. This definition is adapted from the
consensus of the Invasive Fungal Infections
Cooperative Group (IFICG) of the European
Organization for Research and Treatment of
Cancer (EORTC) and the Mycoses Study Group
(MSG) of the National Institute of Allergy and
Infectious Diseases (NIAID), and was originally
applied to immunocompromised patients.7
The data analyzed in this review were identi-
fied initially by search of the Medline database
using the key words “Candida”, “candidemia”, and
“invasive candidiasis”. This review was focused
on adult patients. For the data from Taiwan, the
above key words were combined with “Taiwan”
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Invasive candidiasis has emerged as an important nosocomial infection, especially in critically ill patients.
We review the epidemiology of invasive candidiasis with an emphasis on data from Taiwan. An increasing
incidence of candidemia became apparent from 1980 to the end of the 1990s, followed by relative stabil-
ity. Crude mortality rates of patients with candidemia were in the range of 35% to 60%. Candida albicans
remains the predominant cause of invasive candidiasis in Taiwan and accounts for more than 50% of 
all cases. Candida tropicalis, Candida glabrata and Candida parapsilosis are the three most common non-
albicans Candida species that cause invasive candidiasis. The above four Candida species account for more
than 90% of invasive candidiasis in Taiwan. Overall, invasive Candida isolates have remained highly sus-
ceptible to fluconazole (> 90% susceptibility) over the past two decades. However, periodic surveillance is
needed to monitor antifungal resistance because reduced fluconazole susceptibility in non-albicans
Candida is not an uncommon trend. Voriconazole and echinocandins continue to exhibit excellent in vitro
activity against invasive Candida isolates. [J Formos Med Assoc 2009;108(6):443–451]
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in the search. Only English-language articles that
mentioned invasive Candida isolates were included
in the analysis.
Incidence of Candidemia and 
Invasive Candidiasis
Candida has emerged as one of the major causes
of nosocomial bloodstream infection world-
wide.4,5,8,9 In the United States, Candida is the
fourth leading cause of nosocomial bloodstream
infection, and in Taiwan, it is one of the top three
causes.5,6
The incidence of candidemia is much better
understood than that of invasive candidiasis be-
cause of its clearer disease definition and com-
paratively straightforward diagnosis. The wide
variation in incidence of candidemia is largely
dependent on the period and populations that
are studied. Generally, the incidence of candidemia
in intensive care units (ICUs) is 5–10-fold higher
than that in hospitals overall, and more than
100-fold greater than that in the general popula-
tion.6,10–13 The incidence of nosocomial can-
didemia increased rapidly from 1980 to the end
of the 1990s and has remained relatively stable
thereafter.14–17 However, some studies have re-
ported stable or even decreased incidence during
this period.10,18
In a tertiary medical center in northern Taiwan,
the incidence of nosocomial candidemia in-
creased 36-fold from 1981 (0.08/1000 discharges)
to 2000 (2.9/1000 discharges).19 The incidence
of candidemia in Taiwan and other areas is sum-
marized in Table 1.4,19–26 The higher incidence in
Northern Taiwan (2.9/1000 discharges in 2000)
should not be generalized to other areas of the
country or other hospitals, because the data are
mainly contributed from a large tertiary medical
center in Taipei, which serves a unique popula-
tion subset. Unfortunately, multi-center or na-
tionwide surveillance of this incidence is lacking
in Taiwan.
The true incidence of invasive candidiasis, 
including candidemia and other forms of invasive
Candida infection, is not known because of the
greater difficultly in detecting these diseases. The
estimated incidence of invasive candidiasis in
the United States using the database of Interna-
tional Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) codes was
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Table 1. Estimated incidences of nosocomial candidemia in selected series over the recent 20 years
Studied population 
No. of isolates Year
Rate/1000 admissions or 
Reference
and region rate/1000 discharges
ICUs
Taiwan (Single center) 147 2000–2005 4.3 20
North America 42 1993–1995 9.8 21
(America—multicenter)
Europe (France—multicenter) 57 2001–2002 6.7 22
Hospital-based
North Taiwan (Single center) – 1981 0.08 19
North Taiwan (Single center) – 2000 2.9 19
Central Taiwan (Single center) 91 2001–2003 0.76 23
North America
(Canada—multicenter) 202 1992–1996 0.45 24
(America—nationwide) 1890 1995–2002 0.46 4
Europe
(multi-nation) 2098 1997–1999 0.2–0.38 25
(Italy—nationwide) 569 1997–1999 0.38 26
1.9–2.4 per 1000 hospital discharges during the
period 1996–2003.15 The data obtained by this
method are more comparable to the results from
population-based studies and are likely to be un-
derestimated because of coding mistakes or
missed coding.
Mortality
The impact of invasive candidiasis is not well
known and most data were from candidemia
studies. Candidemia has been shown to be asso-
ciated with high mortality.4,14,27 The crude mor-
tality rate of patients with candidemia is in the
range of 35% to 60% (Table 2).4,14,23,25,28–30 The
mortality rate in Taiwan, however, seems higher
than in other regions. This difference might be
caused partly by greater underlying disease severity
in the portion of the Taiwan population studied.
The published data on invasive candidiasis in
Taiwan were mainly from tertiary medical centers
that comprise a population of patients with more
severe underlying diseases. Like the difference in in-
cidence, the mortality of patients with candidemia
varies in different populations and subpopulations.
For example, ICU patients with candidemia have
a higher mortality rate than non-ICU patients.4
Several studies have attempted to identify the
predictors of fatal outcome, but these may also
have been population dependent.17,27,31,32
Distribution of Candida Species
C. albicans is the most frequent and important
Candida species that causes candidemia world-
wide and accounts for more than 50% of episodes
(Table 3).4,6,14,23,33–38 Although C. albicans is the
predominant species that causes candidemia, the
contribution of non-albicans Candida is rising,
especially in cancer and critically ill patients.39–43
It has been hypothesized that the species shift
has resulted from the increased use of flucona-
zole treatment and prophylaxis.39,42,44 However,
conflicting results have also been reported.45–47
In the studies that have reported species shifts,
Candida glabrata is the main species that has 
increased in proportion to the incidence of 
candidemia.39,41,43,44
Among non-albicans Candida, Candida tropi-
calis, C. glabrata and Candida parapsilosis are the
three most important species that cause can-
didemia and account for around 40% of episodes.
There is wide geographic variation in the distri-
bution of these three Candida species (Table 3).
Invasive candidiasis
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Table 2. Mortality of candidemia in Taiwan and other regions
Region Year No. of isolates Crude mortality Reference
North Taiwan 1994–1995 120 59.3 28
(Single center)
North Taiwan 2000 188 43.1 14
(Single center)
Central Taiwan 2001–2003 91 60 23
(Single center)
South Taiwan 1998 56 60.7 29
(Single center)
North America 1995–2002 1890 39.2 4
(nationwide)
Europe 1997–1999 2098 37.9 25
(multi-nation)
Global 1997–2001 224 34.4 30
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Table 3. Species distribution of invasive Candida isolates in selected series
No. of Species distribution of Candida (%)
Region Year
isolates C. albicans C. glabrata C. tropicalis C. parapsilosis C. krusei
Reference
North Taiwan 1994–2000 1095 50.4 12.0 20.5 14.2 < 1 14
1996–1999 383 55.6 5.2 16.5 17.5 35
1998–2000 98 51.0 13.3 24.5 11.2 36
Central Taiwan 2001–2003 91 64.8 1 19.8 2.2 1.0 23
South Taiwan 1996–2003 403 54 7 24 11 6
Taiwan nationwide 2006 145 56.6 13.8 22 6.2 < 1 37
North America 1995–2002 1890 53.8 18.8 11.1 11.4 2.4 4
Global 1992–2001 6082 55.9 16.2 9.6 13.1 2.5 34
Global 1997–2000 2047 54 16 10 15 2 38
Global 1997–2005 196,508 65.6 11.1 6.9 6.1 2.4 33
Importantly, the distribution pattern of Candida
species reflects the fluconazole susceptibility 
pattern in a given area because some non-albicans
Candida, such as C. glabrata and Candida krusei,
have higher triazole resistance. C. glabrata has
emerged as the most common non-albicans
Candida in North America and other regions
(Table 3) but not in Taiwan. The proportion of
C. tropicalis in Taiwan (16–25%) seems to be
higher than in other regions (5–11%) (Table 3).
Antifungal Susceptibility
Triazoles
Fluconazole, a fungistatic drug introduced in the
early 1990s, has a good safety profile and is the
most widely used antifungal agent for invasive
candidiasis.48–50 The susceptibility of Candida
species to fluconazole, however, is not uniform.
C. albicans is highly susceptible to fluconazole33
but C. glabrata often manifests reduced sus-
ceptibility,15,51 and C. krusei is known to have 
intrinsic resistance to fluconazole.33,52 Despite
high resistance to fluconazole, C. krusei usually
remains susceptible to the newer triazole,
voriconazole.33,51,53
As a result of increasing use of fluconazole 
in treatment and prophylaxis and the associated
emergence of resistance, fluconazole has been the
focus of resistance surveillance.34,54 However, not
all studies have suggested the emergence of flucon-
azole resistance in Candida species. A longitudinal
global surveillance has shown that bloodstream
isolates of Candida remained highly susceptible
(91–100%) to fluconazole from 1992 to 2001, 
Table 4. In vitro activities of fluconazole against common Candida species
Antifungal agents/ No. of Susceptible (%)/resistant (%)
region
Year
isolates C. albicans C. glabrata C. tropicalis C. parapsilosis
Reference
Taiwan
(Single center) 1999–2001 222 100/0 52/12 97/1 98/0 19
(Nationwide) 2002 456 95/2 53/2 96/0 100/0 56
(Nationwide) 2003 391 100/0 72/14 100/0 100/0 57
(Single center) 2005–2007 286 100/0 22/6 100/0 98/0 51
Global 1997–2000 2047 99/– 71/– 98/– 100/– 38
Global* 1997–2005 205,329 97.5/1.5 68.9/15.8 90.4/4.4 93.3/3.6 33
*CLSI disk diffusion testing.
irrespective of geographic origin.34 A study from
Taiwan has also shown stable susceptibility of
Candida blood isolates to fluconazole, despite in-
creasing fluconazole use from 1994 to 2000.14 The
overall susceptibility rate for all invasive isolates
of Candida to fluconazole was 91–96% and the
resistance rate ranged from 0.7% to 2.4%.14,35,55
Species-specific fluconazole susceptibility rates
for the four most common Candida species are
summarized in Table 4.19,33,38,51,56,57 Fluconazole
is highly active against common Candida species,
except for C. glabrata. The susceptibility rate of 
C. glabrata to fluconazole varied widely from 22%
to 72%, and the resistance rate ranged from 2%
Invasive candidiasis
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Table 5. In vitro activities of voriconazole, posaconazole, amphotericin B, caspofungin, micafungin and anidulafungin against
common Candida species
Antifungal agents/ MIC50/MIC90
region
Year
C. albicans C. glabrata C. tropicalis C. parapsilosis
Reference
Voriconazole
Taiwan 1999–2001 0.12/0.12 0.25/4 0.12/0.12 0.12/0.12 19
Taiwan 2005–2007 0.015/0.03 0.5/1 0.12/0.12 0.03/0.06 51
North America 1995–1999 0.03/0.06 0.25/1 0.06/2 0.03/0.06 59
Europe 2001–2006 0.02/0.02 0.25/1 0.02/0.06 0.02/0.03 60
Global 2001–2003 0.008/0.25 0.5/4 0.06/0.25 0.03/0.06 58
Itraconazole
Taiwan 1999–2001 0.03/0.03 0.5/> 64 0.06/0.25 0.12/0.25 19
Taiwan 2005–2007 0.03/0.03 1/1 0.12/0.25 0.06/0.25 51
Global 1992–2004 0.06/0.12 1/2 0.12/0.25 0.25/0.5 15, 61
Posaconazole
Taiwan 2005–2007 0.015/0.03 0.5/0.5 0.06/0.25 0.03/0.06 51
North America 1995–1999 0.03/0.13 1/2 0.06/1 0.03/0.13 59
Europe 2001–2006 0.02/0.02 0.25/1 0.02/0.06 0.02/0.03 60
Amphotericin B
Taiwan 1999–2001 0.25/0.5 1/1 0.25/1 0.5/1 19
Taiwan 2005–2007 1/1 2/2 0.5/1 1/1 51
North America 1995–1999 0.06/0.25 0.13/0.5 0.13/0.5 0.13/0.5 59
Europe 2001–2006 0.06/0.12 0.12/0.25 0.12/0.25 0.12/0.25 60
Caspofungin
Taiwan 2005–2007 0.25/0.25 0.25/0.25 0.25/0.5 1/2 51
North America 1995–1999 0.5/0.5 0.5/1 0.5/1 2/2 59
Europe 2001–2006 0.12/0.25 0.12/0.25 0.12/1 0.5/1 60
Global 2001–2004 0.03/0.06 0.03/0.06 0.03/0.06 0.5/1 15
Micafungin
Taiwan 2005–2007 0.007/0.015 0.06/0.06 0.06/0.12 2/2 51
North America 1995–1999 0.03/0.03 0.03/0.06 0.03/0.06 1/2 59
Global 2004–2005 0.015/0.03 0.015/0.03 0.03/0.06 1/2 15
Anidulafungin
Taiwan 2005–2007 0.015/0.015 0.03/0.03 0.03/0.06 1/2 51
North America 1995–1999 0.03/0.03 0.03/0.13 0.03/0.13 2/2 59
Global 2001–2004 0.03/0.12 0.06/0.12 0.03/0.06 2/4 15
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to 16% (Table 4). A shift from susceptible to sus-
ceptible–dose dependent (S-DD) bloodstream
C. glabrata isolates was noted, despite a stable
fluconazole resistant rate.51 This observation 
provided important information for empirical
antifungal treatment when susceptibility testing
results were not available. The Infectious Diseases
Society of America (IDSA) has recommended
treating disseminated C. glabrata infection with
amphotericin B or high-dose fluconazole (12 mg/
kg/day).50
Susceptibility to voriconazole, itraconazole
and posaconazole is summarized in Table
5.15,19,51,58–61 Voriconazole has shown excellent
potency against Candida species, even for the 
less susceptible species, C. glabrata. Based on the
≤ 1 μg/mL breakpoint, 99% of Candida isolates
were susceptible to voriconazole.58 Similar re-
sults have been observed in Taiwan.51,62 The MIC
breakpoint for itraconazole was ≤ 0.125 μg/mL
for susceptible, 0.25–0.5 μg/mL for S-DD, and
> 0.5 μg/mL for resistant Candida.63 No interpre-
tive breakpoints have been established for posa-
conazole. Higher MICs have also been noted for
C. glabrata (Table 5).
Amphotericin B
As a result of the very narrow range of MICs ob-
tained by the CLSI M27-A2 broth microdilution
method, interpretation of antifungal susceptibility
testing for amphotericin B is controversial and
difficult.63,64 MICs ≤ 1 μg/mL are considered as
susceptible to amphotericin B.64,65 The MIC90 for
all invasive Candida isolates were all ≤ 1 μg/mL, 
except for C. glabrata (Table 5).
Echinocandins
All three echinocandins, caspofungin, anidula-
fungin and micafungin, are highly active against
Candida species, except for C. parapsilosis (Table 5).
The MIC90 values for C. albicans, C. glabrata and
C. tropicalis are all ≤ 1 μg/mL. C. parapsilosis is less
susceptible to echinocandins, with MIC90 ranging
from 2 to 4 μg/mL. The MIC distribution for echi-
nocandins has revealed two groups among Candida
species.66 C. albicans, C. glabrata, C. tropicalis and
C. krusei are all highly susceptible to echinocandins.
In contrast, C. parapsilosis, Candida guilliermondii
and Candida lusitaniae are less susceptible.66–69
Despite these two different susceptibility patterns,
a large global study has shown that more than
99% of isolates were inhibited by ≤ 2 μg/mL of all
three echinocandins.66 For fluconazole-resistant
Candida isolates, anidulafungin has also demon-
strated good potency.67 Overall, all three echino-
candins have retained excellent in vitro activity
against invasive Candida isolates.
Conclusion
Invasive candidiasis has emerged as an impor-
tant nosocomial infection, especially in critically
ill patients. Crude mortality rates of patients with
candidemia are in the range of 35% to 60%. 
C. albicans (>50%) remains the predominant cause
of invasive candidiasis in Taiwan, followed by 
C. tropicalis, C. glabrata and C. parapsilosis. Overall,
invasive Candida isolates have remained highly
susceptible to fluconazole (> 90% susceptibility)
over the past two decades. However, periodic 
surveillance is needed to monitor antifungal
resistance because reduced fluconazole suscepti-
bility in non-albicans Candida is common.
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